The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Purifloh is continuing to face troubles collecting reliable data during its tuberculosis trial
  • The company highlights the issues stem from trial conditions rather than its Free Radical Generator air purification device
  • Shares in the company are trading at $4.91 apiece after a 13.86 per cent drop today

ASX-listed medical company Purifloh has seen its share price suffer today after informing the market of ongoing troubles with its tuberculosis trial.

The company advised it has been unsuccessful in generating reliable baseline data due to issues isolating tuberculosis-causing bacteria from air samples on site.

As a consequence, Purifloh’s share price is down 13.86 per cent, currently sitting at $4.91 apiece, as of 1:34 pm AEST.

Trials testing its Free Radical Generator (FRG) air purification system to eradicate airborne mycobacterium tuberculosis will continue in hospitals despite persistent difficulties.

Difficulties and delays in conducting the trial have been consistent, as outlined across a number of updates by Purifloh this year.

Rapid contamination of the culture by pathogenic molds has continually posed an issue during the trials.

However, according to Purifloh, the troubles in the trials are not due to the function of the FRG device. The company maintains that problems isolating mycobacterium tuberculosis are the cause the issues.

PO3 by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…